Literature DB >> 8759034

Modulation of nicotine-evoked [3H]dopamine release from rat striatal synaptosomes by voltage-sensitive calcium channel ligands.

R J Prince1, K G Fernandes, J C Gregory, I D Martyn, P M Lippiello.   

Abstract

The calcium channel subtypes mediating nicotine-evoked [3H]dopamine release from rat striatal synaptosomes were probed with L-, N-, and P-type calcium channel ligands. Responses to nicotine were blocked by the peptides omega-conotoxin GVIA and omega-agatoxin IVA. The affinity constants for these compounds were consistent with their actions at N- and P-type channels, respectively. Together, these channels mediate at least 90% of the calcium-dependent response to nicotine. The L-type antagonists nifedipine, verapamil, and nicardipine were also effective blockers of nicotine-evoked release with maximal effects of 80-100% inhibition. However, these effects occurred at concentrations 2-3 orders of magnitude higher than those necessary to block L-type channels. Moreover, Bay K8644, an L-type agonist, also blocked nicotine-evoked release. Together, these findings argue strongly against the involvement of L-type channels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759034     DOI: 10.1016/0006-2952(96)00313-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Modulation of potassium-evoked [3H]dopamine release from rat striatal slices by voltage-activated calcium channel ligands: effects of omega-conotoxin-MVIIC.

Authors:  D Dobrev; K Andreas
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

2.  Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons.

Authors:  L Azam; Y Chen; F M Leslie
Journal:  Neuroscience       Date:  2006-12-29       Impact factor: 3.590

3.  The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum.

Authors:  D Dobrev; A S Milde; K Andreas; U Ravens
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.